Business Wire

DXC-TECHNOLOGY

27.4.2022 08:02:20 CEST | Business Wire | Press release

Share
Spanish Logistics Company MRW Speeds Deliveries with DXC Technology and Nutanix

MRW, a leading Spanish provider of urgent transport and logistics services, managing an average of 70 million shipments per year, has awarded DXC Technology and Nutanix a five-year contract to transform MRW’s IT systems with hybrid cloud technologies. With the move, MRW plans to increase the speed and agility of its delivery business while increasing protection against cybersecurity threats.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006245/en/

“Thousands of clients depend on MRW to ship goods to more than 200 destinations around the globe,” said Belen Arrazola, CIO of MRW. “Hybrid cloud technologies from DXC and Nutanix provide us with a flexible platform to accelerate MRW’s ambitious transformation and growth plans, while ensuring the stability and security we need to protect our operations around the clock.”

MRW’s logistics business is powered by two data centers in Barcelona. By deploying hybrid cloud technologies running on Kubernetes containers, MRW expects significant efficiencies across several areas. For example, MRW’s DevOps teams will be able to modernize applications and deploy them to the cloud faster in order to improve the time-to-launch for innovative new services. Priced on a pay-per-use model, the new solution aims to provide MRW with a cost-effective and flexible model to support its growth and development.

As part of the agreement, MRW will tap DXC’s leading security capabilities and expertise to build an immutable backup system, which enables data to be protected and quickly restored in case of a potential ransomware attack.

“MRW is a leading player in logistics and urgent transportation which has seen significant growth in the past couple of years in line with the surge in ecommerce,” said Juan Parra, General Manager, DXC Technology, Iberia. “We will work closely with MRW using hybrid cloud technologies to bring greater flexibility and security to their operations. This project has reinforced our collaboration with Nutanix around hyperconverged infrastructure solutions in Iberia and strengthens our ability to serve customers across multiple industries in the region.”

“We are delighted to be working with MRW and DXC Technology to transform MRW’s IT environment and securely migrate their IT infrastructure,” said Jorge Vázquez, Country Manager of Nutanix Iberia. “We value the great collaboration with DXC, a leader in IT services globally, and look forward to a long future of helping our customers across Spain and Portugal to succeed and grow.”

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private, and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services across the Enterprise Technology Stack to drive new levels of performance, competitiveness, and customer experience. Learn more about how we deliver excellence for our customers and colleagues at DXC.com .

Forward Looking Statements

All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that the results described in such statements will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. Furthermore, many of these risks and uncertainties are currently amplified by and may continue to be amplified by or may, in the future, be amplified by, the ongoing coronavirus disease 2019 (“COVID-19”) pandemic and the impact of varying private and governmental responses that affect our customers, employees, vendors and the economies and communities where they operate. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021, and any updating information in subsequent SEC filings. No assurance can be given that any goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this presentation or to reflect the occurrence of unanticipated events, except as required by law.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release

Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea

Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release

The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea

Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release

Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay

Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release

Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners

Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release

Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye